⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145733 | 1.00 | — | — | |
| SCHEMBL27094829 | 1.00 | — | — | |
| SCHEMBL1444571 | 0.79 | — | — | |
| SCHEMBL10748799 | 0.78 | TP53 (0.36) | — | |
| SCHEMBL10748803 | 0.78 | TP53 (0.36) | — | |
| Hydrochloric Acid SCHEMBL10660012 | 0.77 | — | — | |
| SCHEMBL8978045 | 0.77 | — | — | |
| SCHEMBL4161024 | 0.77 | — | — | |
| SCHEMBL752443 | 0.77 | — | — | |
| SCHEMBL27529857 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| US-20240279338-A1 | Combination Treatment of Cancer | ARES TRADING SA (CH) | 2024-08-22 | — | — | US | disclosed |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-20090155865-A1 | Esterases and their Use for Processes for Kinetic Resolution of Butinolesters | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1937809-A1 | NEW ESTERASES AND THEIR USE FOR PROCESSES FOR KINETIC RESOLUTION OF BUTINOLESTERS | BASF SE (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103192-A1 | CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | WASHINGTON, UNIVERSITY OF (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008046109-A2 | CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | UNIVERSITY OF WASHINGTON (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007042444-A1 | NEW ESTERASES AND THEIR USE FOR PROCESSES FOR KINETIC RESOLUTION OF BUTINOLESTERS | BASF SE (DE) | 2007-04-19 | — | — | WO | disclosed |
| EP-1658302-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | Idenix (Cayman) Limited (KY) | 2006-05-24 | — | — | EP | disclosed |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | IDENIX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005009418-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX (CAYMAN) LIMITED (KY) | 2005-02-03 | — | — | WO | disclosed |